CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5031275_CN31275_0